Atlas Trials

ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Clinical trial NCT06460298 · RECRUITING

Trial details

NCT number
NCT06460298
Sponsor
ProDa BioTech, LLC
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2024-08-20
Primary completion
2026-07-01
Enrollment
51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.